Short answer
Corvus Pharmaceuticals, Inc. (CRVS) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$10M
- +74.7% YoY · −27.0% QoQ
- EPS (diluted)
- −$0.12
- +82.4% YoY · +7.7% QoQ
Source: XBRL data from the Corvus Pharmaceuticals, Inc. (CRVS) Q3 2025 10-Q on SEC EDGAR. USD.
Corvus Pharmaceuticals, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: EU Clinical Trials Regulation fully effective Jan 31, 2025; centralized trial approvals via EU portal may impact development plans
- Updated risk: Cash $65.7M insufficient to fund operations beyond 12 months from 10-Q date; risk of delays or termination of clinical trials without new financing
- Regulatory risk: FDA may not accept foreign clinical data including from Angel Pharmaceuticals' China trials, risking trial delays or failure
- Market risk: Ongoing enrollment challenges and possible adverse events in clinical trials could delay product development and hurt near-term performance
- Financial risk: Accumulated deficit $400M as of Sept 30, 2025; continued net losses $3.0M in nine months 2025 vs $50.2M in 2024; major liquidity need to avoid operational curtailment
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Corvus Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.